This site is intended for healthcare professionals
Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
The Heart Outcomes Prevention Evaluation (HOPE) study of diabetic patients investigated the role of the ACE inhibitor ramipril in diabetic patients with a cardiovascular risk factor.
3577 patients with diabetes were recruited as part of the HOPE study.
The analysis of the diabetic subgroup of the main trial was planned in advance.
Patients were recruited if they:
The primary outcome was the combination of:
Patients were randomised in a two-by-two factorial manner to:
There were significant benefits for the following end-points in those patients randomised to ramipril: